Albuminuria, Type 2 diabetes
Conditions
Brief summary
Questionnaire results: participants’ perspectives toward the feasibility of participation in a trial at home with digital technologies, Number and percentage of urine collections not received at the laboratory or unable to be analyzed, Number and percentage of missed blood pressure or body weight measurements, Treatment adherence: pill count and medication concentration in urine samples
Detailed description
Change from baseline in UACR from start to end of treatment with empagliflozin, Change from baseline in systolic blood pressure, body weight, eGFR, and fasting plasma glucose from start to end of treatment with empagliflozin, (Additive) treatment effects on UACR, systolic blood pressure, body weight, eGFR, and fasting plasma glucose from start to end of treatment after the addition or substitution with finerenone
Interventions
DRUGJardiance 10 mg film-coated tablets
Sponsors
Universitair Medisch Centrum Groningen
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Questionnaire results: participants’ perspectives toward the feasibility of participation in a trial at home with digital technologies, Number and percentage of urine collections not received at the laboratory or unable to be analyzed, Number and percentage of missed blood pressure or body weight measurements, Treatment adherence: pill count and medication concentration in urine samples | — |
Secondary
| Measure | Time frame |
|---|---|
| Change from baseline in UACR from start to end of treatment with empagliflozin, Change from baseline in systolic blood pressure, body weight, eGFR, and fasting plasma glucose from start to end of treatment with empagliflozin, (Additive) treatment effects on UACR, systolic blood pressure, body weight, eGFR, and fasting plasma glucose from start to end of treatment after the addition or substitution with finerenone | — |
Countries
Netherlands
Outcome results
None listed